Indivior Sets $1.03B-$1.08B 2025 Revenue Guidance and Outlines Cost Structure Overhaul

Indivior has outlined its 2025 revenue guidance of $1.03B-$1.08B and plans to overhaul its cost structure through an action agenda. CEO Joseph J. Ciaffoni reported record SUBLOCADE net revenue, driven by strong US performance, positioning the company well for the remainder of the year.

Richmond, VA, July 2, 2025 – Indivior PLC (Nasdaq: INDV) reported its financial results for the second quarter ended June 30, 2025, and announced an increase in its 2025 financial guidance. The company's total net revenue for Q2 increased to $302 million, up 1% from the same period last year, with a notable 9% year-over-year growth in SUBLOCADE® net revenue to $209 million [1].

The strong performance was primarily driven by the U.S. market, where SUBLOCADE® net revenue increased by 9% to $195 million compared to Q2 2024, and 20% compared to Q1 2025. This growth was largely due to volume-driven demand, offsetting the decline in SUBOXONE® Film revenue due to increased generic competition and the discontinuation of PERSERIS in July 2024 [1].

Indivior's Chief Executive Officer, Joe Ciaffoni, stated, "SUBLOCADE® net revenue and pricing stability in SUBOXONE® Film in the U.S. drove solid results in the second quarter, leading us to raise our 2025 financial guidance." The company has also initiated the Indivior Action Agenda, focusing on growing U.S. SUBLOCADE® net revenue and simplifying the organization to generate operational momentum [1].

In response to the strong performance, Indivior has raised its full-year 2025 financial guidance. The new guidance assumes no material change in exchange rates for key currencies compared to 2024 average rates. The revised guidance includes a range of $1,030 million to $1,080 million for total net revenue, and $765 million to $785 million for SUBLOCADE® net revenue [1].

The company also reported a gross margin of 83% in Q2, up from 74% in the same period last year. Non-GAAP gross margin remained at 84%, while SG&A expense increased by 6% to $146 million, primarily due to expected increases in marketing for U.S. SUBLOCADE®. R&D expenses decreased by 20% to $21 million, reflecting the refocusing of the pipeline on existing Phase 2 OUD assets [1].

Indivior's stock is now listed exclusively on the Nasdaq, aligning with the company's capital markets footprint and a stronger focus on SUBLOCADE® growth in the U.S. The company has also been included in the Russell Equity Indexes, effective June 30, 2025 [1].

The company's financial results and business update will be discussed further during a conference call and webcast scheduled for today at 8:00 A.M. EDT. Materials will be available on the Company’s website prior to the event at www.indivior.com [1].

References:
[1] Indivior PLC. (2025, July 31). Indivior reports second-quarter 2025 financial results and raises FY 2025 financial guidance. Retrieved from https://www.indivior.com/en/media/press-releases/indivior-reports-second-quarter-2025-financial-results-and-raises-fy-2025-financial-guidance